Biogen plunks down $1B in cash to expand neuro drug pact with Ionis

The companies previously collaborated to develop a treatment for a rare infant disorder that won FDA approval in December 2016. They will pursue similar drugs under the deal announced Friday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.